Firma Ewopharma, Autor bei News-Research

Ewopharma and Dr. Falk Pharma renew their long-standing partnership – a commitment built to last

29. Mai 2026 Firma EwopharmaPosted in AllgemeinTagged board, clinical, company, disease, ewopharma, falk, freiburg, health, market, network, new, patients, research, strong, with

Ewopharma AG and Dr. Falk Pharma GmbH are extending their distribution partnership of more than 27 years – for many more to come. Under the renewed distribution agreement, Ewopharma continues […]

Sugemalimab Receives I, A Recommendation in ESMO Guideline for Consolidation Therapy in Patients with Stage III NSCLC

16. April 2026 Firma EwopharmaPosted in AllgemeinTagged cancer, cell, cells, cstone, egfr, esmo, ewopharma, market, monotherapy, nsclc, patients, ros1, sugemalimab, tumour, with

Ewopharma is pleased to report that sugemalimab, licensed from partner CStone Pharmaceuticals, has received a I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced […]

Sugemalimab Achieves New Regulatory Milestone: European Commission Approves Stage Ⅲ NSCLC Indication

17. Dezember 202522. Dezember 2025 Firma EwopharmaPosted in AllgemeinTagged alk, cancer, cell, cells, chemoradiotherapy, cstone, egfr, ewopharma, monotherapy, nsclc, patients, ros1, sugemalimab, tumour, with

Ewopharma is pleased to report an important new regulatory milestone for sugemalimab licensed from Chinese partner CStone Pharmaceuticals. In late November 2025, the European Commission (EC) granted approval for a […]

Ewopharma AG Announces Exclusive Distribution Agreement for Cardiovascular Solutions in Bulgaria

15. April 202511. April 2025 Firma EwopharmaPosted in MedizintechnikTagged balloon, coatings, dcb, eluting, ewopharma, healthcare, market, medical, patients, restenosis, solutions, translumina, treatment, vessel, with

Effective June 1, 2024, Ewopharma AG has the exclusive licence to distribute Translumina’s drug-eluting stents (DES) and Blue Medical’s drug-coated balloon (DCB) technologies in Bulgaria. The agreement includes two key […]

AllergyCare AG Becomes Part Of Ewopharma Group

3. Juni 20243. Juni 2024 Firma EwopharmaPosted in AllgemeinTagged aida, Business, company, customers, ewopharma, health, healthcare, home?, market, new, pharmaceutical, privileged, services, treatment, with

Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of AllergyCare AG, a Swiss distribution company of pharmaceutical […]

Ewopharma and CStone enter into a Strategic Partnership for Sugemalimab in Central Eastern Europe and Switzerland

27. Mai 202427. Mai 2024 Firma EwopharmaPosted in AllgemeinTagged cancer, cee, cell, clinical, ewopharma, lymphoma, medical, new, nsclc, patients, Payment, research, revenues, treatment, with

Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovationdriven biopharmaceutical company focused on the research and development of anti-cancer […]

Neomed s.r.o. becomes part of Ewopharma Group

31. Mai 2023 Firma EwopharmaPosted in FirmeninternTagged company, cosmetic, devices, ewopharma, healthcare, intraocular, lenses, logistics, market, medical, new, patients, pharmaceutical, services, with

Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of Neomed s.r.o., a Czech Distribution company of pharmaceuticals, […]